Cargando…
A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells
SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer that lacks an estrogen receptor, the progesterone receptor and the human epidermal growth factor receptor 2 (HER2), making it unsuitable for hormonal- or HER2-based therapy. TNBC is known...
Autores principales: | Tukaramrao, Diwakar Bastihalli, Malla, Saloni, Saraiya, Siddharth, Hanely, Ross Allen, Ray, Aniruddha, Kumari, Shikha, Raman, Dayanidhi, Tiwari, Amit K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074041/ https://www.ncbi.nlm.nih.gov/pubmed/33919653 http://dx.doi.org/10.3390/cancers13081954 |
Ejemplares similares
-
IND-2, a Quinoline Derivative, Inhibits the Proliferation of Prostate Cancer Cells by Inducing Oxidative Stress, Apoptosis and Inhibiting Topoisomerase II
por: Balaji, Swapnaa, et al.
Publicado: (2022) -
Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness
por: Sridharan, Sangita, et al.
Publicado: (2019) -
Novel Thienopyrimidine Derivative, RP-010, Induces β-Catenin Fragmentation and Is Efficacious against Prostate Cancer Cells
por: Amawi, Haneen, et al.
Publicado: (2019) -
Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes
por: Zajac, Kelsee K., et al.
Publicado: (2023) -
Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents
por: Lagardère, Prisca, et al.
Publicado: (2021)